Cargando…
Targeting allosteric binding site in methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) to identify natural product inhibitors via structure-based computational approach
Cancer has been viewed as one of the deadliest diseases worldwide. Among various types of cancer, breast cancer is the most common type of cancer in women. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is a promising druggable target and is overexpressed in cancerous cells, like, breast cancer....
Autores principales: | Rana, Nisarg, Patel, Dhaval, Parmar, Meet, Mukherjee, Nandini, Jha, Prakash C., Manhas, Anu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593809/ https://www.ncbi.nlm.nih.gov/pubmed/37872243 http://dx.doi.org/10.1038/s41598-023-45175-3 |
Ejemplares similares
-
Xanthine Derivatives
Reveal an Allosteric Binding
Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2)
por: Lee, Lung-Chun, et al.
Publicado: (2021) -
The catalytic mechanism of the mitochondrial methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2)
por: Zhao, Li Na, et al.
Publicado: (2022) -
Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
por: Jha, Vibhu, et al.
Publicado: (2023) -
Expression and Prognostic Value Identification of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Brain Low-Grade Glioma
por: Shi, Lu-feng, et al.
Publicado: (2021) -
Human mitochondrial MTHFD2 is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase
por: Shin, Minhye, et al.
Publicado: (2017)